CLINICAL TRIALS PROFILE FOR IXAZOMIB CITRATE

All Clinical Trials for IXAZOMIB CITRATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00963820 ↗	Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma	Completed	Millennium Pharmaceuticals, Inc.	Phase 1	2009-10-01	The primary objective of this study is to determine the safety profile, tolerability, and maximum tolerated dose of ixazomib citrate (MLN9708) when taken orally on a weekly dosing schedule by patients with relapsed and refractory multiple myeloma (RRMM). Secondary objectives include pharmacokinetics and response rates.
NCT01415882 ↗	Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib	Recruiting	National Cancer Institute (NCI)	Phase 2	2012-01-31	This phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT01415882 ↗	Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib	Recruiting	Mayo Clinic	Phase 2	2012-01-31	This phase II trial studies how well ixazomib citrate works in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) but is not resistant to bortezomib (refractory). Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
NCT01718743 ↗	Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma	Active, not recruiting	Millennium Pharmaceuticals, Inc.	Phase 2	2012-12-03	This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving ixazomib citrate together with lenalidomide may be effective in treating multiple myeloma.
NCT01718743 ↗	Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma	Active, not recruiting	National Cancer Institute (NCI)	Phase 2	2012-12-03	This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving ixazomib citrate together with lenalidomide may be effective in treating multiple myeloma.
NCT01718743 ↗	Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma	Active, not recruiting	M.D. Anderson Cancer Center	Phase 2	2012-12-03	This phase II trial studies how well ixazomib citrate and lenalidomide after stem cell transplant work in treating patients with newly diagnosed multiple myeloma. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Giving ixazomib citrate together with lenalidomide may be effective in treating multiple myeloma.
NCT01864018 ↗	Ixazomib Citrate, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis	Active, not recruiting	National Cancer Institute (NCI)	Phase 1/Phase 2	2013-08-20	This phase I/II trial studies the side effects and the best dose of cyclophosphamide when given together with ixazomib citrate and dexamethasone in treating patients with previously untreated symptomatic multiple myeloma or light chain amyloidosis. Drugs used in chemotherapy, such as cyclophosphamide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ixazomib citrate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving cyclophosphamide together with ixazomib citrate and dexamethasone may be a better treatment for multiple myeloma or light chain amyloidosis.

Clinical Trial Conditions for IXAZOMIB CITRATE

Condition Name

Condition Name for IXAZOMIB CITRATE
Intervention	Trials
Recurrent Plasma Cell Myeloma	11
Plasma Cell Myeloma	7
Refractory Plasma Cell Myeloma	7
Multiple Myeloma	4

Condition MeSH

Condition MeSH for IXAZOMIB CITRATE
Intervention	Trials
Neoplasms, Plasma Cell	24
Multiple Myeloma	24
Lymphoma	4
Lymphoma, Mantle-Cell	3

Clinical Trial Locations for IXAZOMIB CITRATE

Trials by Country

Trials by Country for IXAZOMIB CITRATE
Location	Trials
United States	141
Brazil	19
United Kingdom	18
Italy	17
Germany	15

Trials by US State

Trials by US State for IXAZOMIB CITRATE
Location	Trials
Minnesota	15
California	9
Texas	8
Georgia	7
Washington	7

Clinical Trial Progress for IXAZOMIB CITRATE

Clinical Trial Phase

Clinical Trial Phase for IXAZOMIB CITRATE
Clinical Trial Phase	Trials
Phase 3	4
Phase 2	19
Phase 1/Phase 2	9

Clinical Trial Status

Clinical Trial Status for IXAZOMIB CITRATE
Clinical Trial Phase	Trials
Active, not recruiting	18
Recruiting	10
Completed	4

Clinical Trial Sponsors for IXAZOMIB CITRATE

Sponsor Name

Sponsor Name for IXAZOMIB CITRATE
Sponsor	Trials
National Cancer Institute (NCI)	28
Millennium Pharmaceuticals, Inc.	10
Mayo Clinic	10

Sponsor Type

Sponsor Type for IXAZOMIB CITRATE
Sponsor	Trials
Other	34
NIH	28
Industry	16

Last updated: April 28, 2026

Ixazomib Citrate: Clinical Trials Update, Market Analysis, and Projection

What is ixazomib citrate and where is it used commercially?

Ixazomib citrate (oral proteasome inhibitor; Ninlaro, Takeda) is approved for multiple myeloma (MM) treatment in combination regimens. It is used in lines of therapy where proteasome inhibition plus other agents improves response and disease control, including standard backbone combinations with immunomodulatory drugs and corticosteroids.

Key market framing (U.S.-centric, based on publicly observable label footprint and typical payer behavior):

• Core use: relapsed/refractory multiple myeloma (RRMM) and related treatment sequencing.
• Primary commercial demand drivers:
  • Oral administration convenience vs infused/IV alternatives
  • Regimen adoption in RRMM, particularly combinations that fit standard treatment pathways
  • Retention in community and specialty settings where oral regimens improve adherence and clinic throughput

What is the current clinical-trial landscape for ixazomib citrate?

Ixazomib has a mature approval base and an extensive development history. Public trial activity concentrates on:

• New combinations (changing partner backbone drugs)
• Earlier-line and maintenance concepts
• Retreatment / sequencing questions
• Expansion into adjacent plasma-cell disorder contexts (where mechanistic fit exists)

Status overview (high-level):

• Mature phase: Most of the program is in post-marketing, combination optimization, and label-expansion attempts rather than first-in-class discovery-level development.
• Operational expectation: Active late-stage trials are less frequent than in early program years, with ongoing work often focused on regimen selection and subpopulation outcomes.

Implication for market timing:

• Near-term revenue change from “trial breakthrough” is more likely to come from label expansion or stronger evidence that changes standard-of-care sequencing than from incremental efficacy signals without regulatory action.

Which late-stage trials (and pivotal evidence) most impact expectations?

Without an explicit list of trial identifiers and latest enrollment/primary completion dates, the only defensible statement is that ixazomib’s clinical value in market forecasting is driven primarily by:

• Its existing regulatory approvals and regimen positioning
• Ongoing evidence that supports or adjusts standard sequencing in RRMM

That means projections should be modeled against (1) competitive intensity, (2) payer access patterns for oral proteasome inhibitors, and (3) whether new data strengthens or weakens placement in second-line and beyond.

How does ixazomib’s commercial performance map to market dynamics?

Ixazomib’s sales are exposed to multiple RRMM market forces:

1) Competitive landscape

• Competition comes from other proteasome inhibitors, including IV and oral agents, and from combination regimens using newer agents (immunotherapies and next-generation agents) that can shift treatment patterns.

2) Sequencing risk

• If newer standards move earlier in the treatment line, ixazomib can face reduced addressable population in later lines.
• Conversely, if oral proteasome inhibitor combinations retain a durable place in RRMM pathways, ixazomib benefits from regimen continuity and real-world tolerability.

3) Geographic access and reimbursement

• Oral oncology drugs tend to show fast adoption in markets with supportive oral reimbursement pathways.
• Any tightening of prior authorization criteria can affect net sales more than gross prescription counts.

What is the market size and how does ixazomib fit?

Public market sizing for RRMM and proteasome inhibitor segments varies by source and methodology. The correct way to project ixazomib is to model:

• Addressable MM population by line of therapy
• Market share within proteasome inhibitor-containing regimens
• Treatment duration and switching
• Real-world persistence in combination therapy

Given the lack of explicit quantitative trial tables in the prompt, a projection that claims exact dollar forecasts without a defined dataset would not be actionable. A business-grade approach is to provide a model structure and the drivers that determine the range.

Projection model inputs (business levers):

• Patient pool (P): RRMM prevalence and incidence-adjusted treated population
• Line mix (L): percentage of patients receiving proteasome inhibitor combinations in 2L, 3L, 4L+
• Share (S): proportion of proteasome inhibitor regimen uptake attributable to ixazomib
• Intensity (I): regimen selection frequency and average duration
• Net price factor (NP): WAC less rebates/discounts; shifts with competition and contracting

Ixazomib revenue equation (template):

• Revenue = P × L × S × I × NP

What is the forward projection for ixazomib sales growth or decline?

A high-level directional view is possible:

• Base case: gradual erosion is typical as RRMM standards evolve and newer agents capture earlier lines; however, oral convenience can slow erosion by maintaining uptake in community settings and combination regimens.
• Upside case: label expansion or strong regimen evidence that improves placement in earlier lines or improves response depth can stabilize share.
• Downside case: intensifying competitive pressure and payer restrictions can reduce net share even if prescriptions remain stable.

What clinical-trial updates would most move the needle for the market forecast?

For ixazomib, the commercially material clinical updates are those that:

• Change line-of-therapy placement in RRMM standards
• Improve progression-free survival enough to shift payer and guideline adoption
• Support new combination backbones that displace competitor regimens
• Reduce discontinuation rates (toxicity profile) enough to increase persistence

How to benchmark ixazomib versus the proteasome inhibitor class?

Benchmarking should be done on:

• Oral vs IV administration advantage (adherence and clinic workflow)
• Regimen compatibility with dominant RRMM backbones
• Share-of-proteasome in standard-of-care combinations

Interpretation for investor-grade modeling:

• If ixazomib keeps a stable share of the oral proteasome inhibitor segment, revenue decline can remain modest.
• If share shifts to competing oral proteasome inhibitors or newer agent-centric regimens, revenue can fall more sharply.

Key risks to incorporate in 12- to 36-month projections

Clinical and regulatory

• Trials fail to translate into label changes or guideline adoption
• Safety/tolerability concerns in expanded populations

Competitive

• More aggressive contracting to win share
• Increased preference for regimens anchored in other drug classes

Commercial

• Net price pressure due to rebate intensity
• Prior authorization friction for oral oncology drugs

Actionable market projection framework (scenario ranges, not point claims)

Because no quantitative input dataset is provided in the prompt, projections below are structured as scenario logic rather than precise revenue numbers.

Scenario	Assumptions	Expected commercial outcome
Base	Stable placement in existing RRMM combinations; modest share pressure	Low-to-mid single digit annual revenue decline
Upside	Evidence strengthens earlier-line regimen use; improved persistence	Revenue stabilizes or returns to low growth
Downside	Loss of share from dominant competitors; payer restrictions increase	High single digit decline or faster erosion

Key Takeaways

• Ixazomib is an established RRMM proteasome inhibitor whose near-term commercial trajectory is driven less by early-stage innovation and more by regimen placement, payer access, and competitive contracting.
• The most market-moving clinical updates are those that shift line-of-therapy positioning, strengthen combination adoption, or improve persistence via tolerability.
• Revenue projections should be modeled using patient pool by line, proteasome regimen share, treatment intensity/persistence, and net price factors, with scenario logic for competitive and payer-driven share loss.

---

FAQs

1) Is ixazomib primarily used for relapsed or frontline multiple myeloma?
Ixazomib’s core use is in relapsed/refractory multiple myeloma within combination regimens.

2) What type of trial result would most improve ixazomib’s market outlook?
Evidence that changes sequencing (earlier-line adoption), improves survival endpoints enough for guideline uptake, or increases treatment persistence.

3) How does oral administration affect market performance for ixazomib?
It supports easier delivery and clinic throughput and can improve persistence and adherence relative to IV regimens, which can slow share erosion.

4) What are the biggest commercial risks for ixazomib over the next 1 to 3 years?
Net price pressure, payer restrictions, and competitive displacement as newer standards move earlier in therapy.

5) How should ixazomib be forecast in an investment model?
Use a scenario framework anchored on treated RRMM population by line, proteasome regimen share, treatment duration, and net price factors.

---

References

[1] FDA. “Ninlaro (ixazomib) prescribing information.” U.S. Food and Drug Administration.
[2] EMA. “Ninlaro (ixazomib) product information.” European Medicines Agency.
[3] Takeda. “Ninlaro (ixazomib) clinical studies and label information.” Takeda official resources.
[4] ClinicalTrials.gov. “Ixazomib studies.” U.S. National Library of Medicine.